Liraglutide Reduces Kidney Damage Markers in Diabetes by Lowering Inflammation and Oxidative Stress | Research

The takeaway

Three months of liraglutide treatment reduced kidney damage, inflammation, and oxidative stress in type 2 diabetes patients, with the greatest kidney benefits in those with the worst baseline kidney function.

Greatest benefit in worst kidneys
Patients with the highest baseline albuminuria showed the largest reductions in kidney damage markers, suggesting liraglutide may be most valuable for patients already developing diabetic kidney disease.

What the researchers found

Three months of liraglutide treatment significantly reduced albuminuria in type 2 diabetes patients with both microalbuminuria and macroalbuminuria, with greater reductions in patients who had worse kidney function at baseline. Liraglutide also decreased inflammatory markers (TNF-α, IL-6, MCP-1) and oxidative stress markers (MDA) while increasing antioxidant enzymes (SOD, glutathione peroxidase) across all patient groups. The degree of albuminuria reduction correlated with improvements in oxidative stress and inflammation, suggesting these mechanisms underlie liraglutide's kidney-protective effects. Blood sugar, HbA1c, and BMI also improved in all groups.

Why it matters

Diabetic kidney disease is the leading cause of kidney failure globally. This study provides clinical evidence that liraglutide's kidney-protective effects are linked to reducing oxidative stress and inflammation — not just improving blood sugar. Importantly, patients with the worst kidney damage (highest albuminuria) benefited the most, suggesting this GLP-1 peptide drug could be particularly valuable for patients already developing kidney complications.

The numbers in context

n=107 · 3 UACR groups · fasting glucose, HbA1c, BMI all decreased (p<0.05) · UACR decreased in groups II (p=0.005) and III (p=0.001) · TNF-α, IL-6, MCP-1, MDA decreased · SOD and GPx increased (all p<0.05)

How the study worked

This prospective study enrolled 107 type 2 diabetes patients initiating liraglutide, categorized into three groups by baseline urinary albumin-to-creatinine ratio (UACR): normal (<30 mg/g), microalbuminuria (30-300 mg/g), and macroalbuminuria (>300 mg/g). Before and after 3 months of treatment, researchers measured metabolic parameters, kidney function markers, and oxidative stress/inflammation biomarkers including TNF-α, IL-6, MCP-1, MDA, SOD, and glutathione peroxidase.

Who was studied

107 type 2 diabetes patients initiating liraglutide, stratified by baseline urinary albumin-to-creatinine ratio

What this study cannot tell us

This is a single-arm study with no control group, so improvements could partly reflect concurrent lifestyle changes or natural regression to the mean. The 3-month follow-up is relatively short for assessing kidney outcomes. The sample size of 107 patients is moderate, with smaller numbers in each UACR subgroup. The study did not account for other kidney-protective medications patients may have been taking.

How to read the evidence

This is a prospective observational study with 107 patients but no control group. While the pre-post design with biomarker correlations provides suggestive evidence, the lack of randomization and a comparator group means the observed improvements cannot be definitively attributed to liraglutide alone.

When this study was published

Published in 2024, this study reflects current clinical interest in the non-glycemic benefits of GLP-1 receptor agonists, particularly kidney protection in diabetic patients.

The bigger picture

This study adds to the growing body of evidence that GLP-1 receptor agonists protect the kidneys beyond their blood sugar-lowering effects. By showing that liraglutide reduces oxidative stress and inflammation in proportion to its kidney benefits, it provides mechanistic insight into the renal protection observed in large cardiovascular outcome trials like LEADER. These findings support using GLP-1 drugs earlier in patients developing diabetic kidney disease.

Questions still open

Does liraglutide's kidney-protective benefit persist or increase beyond 3 months of treatment?
How do liraglutide's renal effects compare to SGLT2 inhibitors, which also protect the kidneys through anti-inflammatory mechanisms?
Could combining liraglutide with an SGLT2 inhibitor provide additive kidney protection through complementary antioxidant and anti-inflammatory pathways?

Common questions

Why does albuminuria matter and how does liraglutide help?

Albuminuria (protein leaking into urine) is an early sign that diabetes is damaging the kidneys. This study showed liraglutide reduced albuminuria in patients with moderate and severe kidney leakage. The improvement was linked to reduced inflammation and oxidative stress, suggesting the drug protects kidney cells from the damage caused by diabetes.

If patients with worse kidney function improved more, should liraglutide be started earlier or later?

The finding that patients with more kidney damage improved most suggests liraglutide is especially beneficial when kidney disease is already developing. However, starting treatment earlier — before significant damage occurs — could potentially prevent kidney problems from developing in the first place. Ideally, GLP-1 drugs should be considered early in diabetes management for patients at risk of kidney complications.

Read the original research

Effects of 3-month liraglutide treatment on oxidative stress and inflammation in type 2 diabetes patients with different urinary albumin-to-creatinine ratio categories.

Medicine, 103(47), e40438

View on PubMed ↗Publisher’s paper ↗

Citation

Chen, Shumei; He, Meiqing; Qin, Yufan; Tian, Jing; Liang, Zerong; Li, Ying; Wang, Peihua; Zhang, Youzhi; Zhou, Cui; Xiao, Juan. (2024). Effects of 3-month liraglutide treatment on oxidative stress and inflammation in type 2 diabetes patients with different urinary albumin-to-creatinine ratio categories.. Medicine, 103(47), e40438. https://doi.org/10.1097/MD.0000000000040438